EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells

References

• American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society, 2014.
   Google Scholar
• Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62:220-41; PMID:22700443
   PubMed Web of Science ®Google Scholar
• Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369:1023-34; PMID:24024839; http://dx.doi.org/10.1056/NEJMoa1305275
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358:1160-74; PMID:18337605; http://dx.doi.org/10.1056/NEJMra0707704
   PubMed Web of Science ®Google Scholar
• Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011; 10:1533-41; PMID:21878654; http://dx.doi.org/10.1158/1535-7163.MCT-11-0047
   PubMed Web of Science ®Google Scholar
• Wei Y, Zou Z, Becker N, Anderson M, Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell 2013; 154:1269-84; PMID:24034250; http://dx.doi.org/10.1016/j.cell.2013.08.015
   PubMed Web of Science ®Google Scholar
• Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R, Piperdi B. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib. J Thoracic Oncol 2013; 8:693-702; PMID:23575415; http://dx.doi.org/10.1097/JTO.0b013e31828c7210
   PubMed Web of Science ®Google Scholar
• Li YY, Lam SK, Mak JC, Zheng CY, Ho JC. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer 2013; 81:354-61; PMID:23769318; http://dx.doi.org/10.1016/j.lungcan.2013.05.012
   PubMed Web of Science ®Google Scholar
• Bokobza SM, Jiang Y, Weber AM, Devery AM, Ryan AJ. Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells. Oncotarget 2014; 5:4765-78; PMID:24946858
   PubMedGoogle Scholar
• Dragowska WH, Weppler SA, Wang JC, Wong LY, Kapanen AI, Rawji JS, Warburton C, Qadir MA, Donohue E, Roberge M, et al. Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PloS One 2013; 8:e76503; PMID:24146879; http://dx.doi.org/10.1371/journal.pone.0076503
   PubMed Web of Science ®Google Scholar
• Eimer S, Belaud-Rotureau MA, Airiau K, Jeanneteau M, Laharanne E, Veron N, Vital A, Loiseau H, Merlio JP, Belloc F. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol Ther 2011; 11:1017-27; PMID:21508666; http://dx.doi.org/10.4161/cbt.11.12.15693
   PubMed Web of Science ®Google Scholar
• Xu L, Beckebaum S, Iacob S, Wu G, Kaiser GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol 2014; 60:590-8; PMID:24211739; http://dx.doi.org/10.1016/j.jhep.2013.10.028
   PubMed Web of Science ®Google Scholar
• Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X, Yuan GC, Orkin SH. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 2008; 32:491-502; PMID:19026780; http://dx.doi.org/10.1016/j.molcel.2008.10.016
   PubMed Web of Science ®Google Scholar
• McCabe MT, Creasy CL. EZH2 as a potential target in cancer therapy. Epigenomics 2014; 6:341-51; PMID:25111487; http://dx.doi.org/10.2217/epi.14.23
   PubMed Web of Science ®Google Scholar
• Shen L, Cui J, Liang S, Pang Y, Liu P. Update of research on the role of EZH2 in cancer progression. OncoTargets Ther 2013; 6:321-4; PMID:23589697; http://dx.doi.org/10.2147/OTT.S42453
   PubMed Web of Science ®Google Scholar
• Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009; 625:131-42; PMID:19836388; http://dx.doi.org/10.1016/j.ejphar.2009.10.011
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51; PMID:16397526; http://dx.doi.org/10.1038/nrc1779
   PubMed Web of Science ®Google Scholar
• Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours–lessons from the past. Nat Rev Clin Oncol 2013; 10:256-66; PMID:23546521; http://dx.doi.org/10.1038/nrclinonc.2013.42
   PubMed Web of Science ®Google Scholar
• Benoit YD, Witherspoon MS, Laursen KB, Guezguez A, Beausejour M, Beaulieu JF, Lipkin SM, Gudas LJ. Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells. Exp Cell Res 2013; 319:1463-70; PMID:23588203; http://dx.doi.org/10.1016/j.yexcr.2013.04.006
   PubMed Web of Science ®Google Scholar
• Benoit YD, Laursen KB, Witherspoon MS, Lipkin SM, Gudas LJ. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells. J Cell Physiol 2013; 228:764-72; PMID:23001792; http://dx.doi.org/10.1002/jcp.24224
   PubMed Web of Science ®Google Scholar
• Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Falth M, Sultmann H, Holzer A, Hoppe-Seyler K, Hoppe-Seyler F. EZH2 depletion blocks the proliferation of colon cancer cells. PloS One 2011; 6:e21651; PMID:21765901; http://dx.doi.org/10.1371/journal.pone.0021651
   PubMedGoogle Scholar
• Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, Liu F, Gao C, Huang XP, Kuznetsova E, et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol 2013; 8:1324-34; PMID:23614352; http://dx.doi.org/10.1021/cb400133j
   PubMed Web of Science ®Google Scholar
• Barth S, Glick D, Macleod KF. Autophagy: assays and artifacts. J Pathol 2010; 221:117-24; PMID:20225337; http://dx.doi.org/10.1002/path.2694
   PubMed Web of Science ®Google Scholar
• Komatsu M, Kageyama S, Ichimura Y. p62/SQSTM1/A170: physiology and pathology. Pharmacol Res 2012; 66:457-62; PMID:22841931; http://dx.doi.org/10.1016/j.phrs.2012.07.004
   PubMed Web of Science ®Google Scholar
• Tanida I, Minematsu-Ikeguchi N, Ueno T, Kominami E. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy 2005; 1:84-91; PMID:16874052; http://dx.doi.org/10.4161/auto.1.2.1697
   PubMed Web of Science ®Google Scholar
• Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, Maiuri MC, Kroemer G. Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta 2009; 1793:1524-32; PMID:19371598; http://dx.doi.org/10.1016/j.bbamcr.2009.01.006
   PubMed Web of Science ®Google Scholar
• Chen Y, Klionsky DJ. The regulation of autophagy–unanswered questions. J Cell Sci 2011; 124:161-70; PMID:21187343; http://dx.doi.org/10.1242/jcs.064576
   PubMed Web of Science ®Google Scholar
• Han CB, Li F, Ma JT, Zou HW. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012; 30:741-7; PMID:23075074; http://dx.doi.org/10.3109/07357907.2012.732159
   PubMed Web of Science ®Google Scholar
• Remon J, Moran T, Reguart N, Majem M, Carcereny E, Lianes P. Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome. Cancer Treat Rev 2014; 40:723-9; PMID:24759598; http://dx.doi.org/10.1016/j.ctrv.2014.03.006
   PubMed Web of Science ®Google Scholar
• Mok TS, Lee K, Leung L. Targeting epidermal growth factor receptor in the management of lung cancer. Semin Oncol 2014; 41:101-9; PMID:24565584; http://dx.doi.org/10.1053/j.seminoncol.2013.12.010
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2014. http://www.R-project.org/
   Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. BioRxiv 2014. http://dx.doi.org/10.1101/002832
   Google Scholar